European Journal of Molecular & Clinical

ISSN 2515-8260 Volume 05, Issue 01, 2018

Pharmaceutical formulation design for enhancing solubility, stability, and bioavailability of poorly water-soluble drugs: An Analytical Perspective

Shatakshi Lall
Asst. Professor, School of Pharmacy, Graphic Era Hill University,
Dehradun, Uttarakhand India 248002
DOI:10.48047/ejmcm/v05/i01/77

Abstract

The development of pharmaceutical formulations for drugs with poor water solubility presents significant challenges in achieving desired therapeutic outcomes. These drugs have limited solubility, which result in suboptimal bioavailability, reduced stability, and compromised efficacy. To overcome challenges, formulation strategies required to enhance drug solubility, stability, and bioavailability. Several approaches explored in pharmaceutical formulation design to address the solubility issues with poorly water-soluble drugs. These approaches particle size reduction, solid dispersion, lipid-based formulations, cyclodextrin complexation, and nanotechnology-based delivery systems. Particle size reduction techniques, such as micronization and nanonization, can significantly increase the surface area and improve dissolution rates, thereby enhancing drug solubility. Techniques such as hot melt extrusion and spray drying help disperse medications with low solubility into water-loving carriers, which boosts their solubility and ability to dissolve. Formulations that are lipid-based, like self-emulsifying drug delivery systems (SEDDS) and lipid nanoparticles, can optimize solubility and absorption of drugs by taking advantage of naturally occurring physiological pathways connected to lipid digestion and absorption. Furthermore, cyclodextrins have the capability to form complexes that aid in the increased solubility and preserving stability of medications that have little water solubility.

Keywords- Pharmaceutical formulations for drugs, Exploration and advancement in Pharma.

Introduction

The employment of the mixing and matching of chemicals along with the rapid testing of multiple samples simultaneously, methodologies in the field of pharmaceutical exploration has given rise to an upsurge in the count of drug candidates exhibiting deficient aqueous solubility. In recent times, an estimated 70% of novel drug candidates have demonstrated a

ISSN 2515-8260 Volume 05, Issue 01, 2018

dearth in solubility, thereby posing significant challenges in terms of formulation and development. Additionally, 40% of the oral medications currently available are virtually insoluble. The application of cyclodextrin derivatives and co-solvents further amplifies their capacity to dissolve substances. Moreover, delivery systems based on nanotechnology, such as nanosuspensions, nanoemulsions, and polymeric nanoparticles, offer a foundation for enhanced drug solubility, stability, and precise administration. By harnessing these formulation design strategies, scientists and pharmaceutical manufacturers can tackle the complexities associated with poorly water-soluble medications, thereby fostering heightened bioavailability, improved patient adherence, and ultimately, superior therapeutic outcomes. Additional exploration and advancement in this realm possess immense potential to revolutionize drug delivery and broaden the array of effective treatment alternatives.

According to Kawabata, Wada, Nakatani, Yamada, and Onoue (2011), formulation design for poorly water-soluble drugs challenges arising from the inadequate solubility of medicinal candidates pose significant hurdles within the realm of drug exploration and advancement. The presence of water and its capacity to dissolve a drug are pivotal factors in determining the speed at which a drug dissolves. When a drug exhibits low solubility, its limited ability to dissolve often results in diminished bioavailability when administered orally. Generally, substances with solubility levels in water of less than 100 μg/mL are likely to face difficulty in being absorbed in the body due to difficulty in dissolution. In such it necessary to increase the dosage to achieve therapeutic concentrations of the drug in the bloodstream. However, augmenting the dosage can occasionally When taken orally, certain drugs can cause toxic effects in the digestive system, which might make it harder for patients to stick to their prescribed plan.

Drug product formulation design encounters significant challenges when confronted with highly concentrated poorly soluble drugs. Augmenting the drug load can yield undesirable characteristics in the powdered form, such as compromised flowability and a propensity to adhere during processes like granulation and tableting. Moreover, the development and manufacturing of such pharmaceutical products necessitate an augmented quantity of active pharmaceutical ingredient (API), resulting in escalated production expenditures.

The limited solubility of novel drug candidates can also bear implications during the drug discovery phase's in vitro assay performance. In the area of drug development, a variety of in

ISSN 2515-8260 Volume 05, Issue 01, 2018

vitro cell culture tests are used to evaluate various qualities of potential drugs, such as how effective they are, how well they penetrate cell membranes, and whether they have any genotoxic effects.The constraints on a drug's ability to dissolve or form solid particles in the test environment can undermine the reliability of the data gathered regarding the drug's characteristics in laboratory settings.

In the early stages of drug development, these solubility limitations can negatively impact the quality of information derived from in vivo toxicity evaluations. Toxicological examinations generally necessitate higher levels of exposure compared to pharmacological or pharmacokinetic studies, aiming to ensure safety. If a potential drug candidate demonstrates inadequate solubility, attaining the requisite exposure levels for accurate toxicity assessment becomes a formidable task. In the realm of clinical application, the limited bioavailability of a drug substance exhibiting poor solubility can impede favorable clinical outcomes and impede its therapeutic potential. This underscores the paramount importance of addressing solubility challenges during the process of drug exploration and advancement, ultimately optimizing the effectiveness and safety of pharmaceutical products.

When dealing with poorly water-soluble drugs that also exhibit poor membrane permeability, falling under Biopharmaceutics Classification System (BCS) class IV, formulation strategies have limited efficacy in enhancing their absorption. When drugs are categorized as BCS class II drugs, meaning they have low water solubility and good membrane permeability, they often require supplemental formulation to be effectively taken orally. Through performing lead optimization during the drug discovery stage, structural alterations can be made in order to achieve desired physicochemical properties. Specific strategies can then be used to enhance its solubility and dissolution rate, such as particle size reduction, amorphous solid dispersion, lipid-based formulations, cyclodextrin complexation, and salt formation (Fahr & Liu, 2007). All of these will ultimately improve its bioavailability.

Particle size reduction techniques, including micronization and nanosizing, can significantly increase the surface area of the drug particles, leading to improved dissolution properties. Amorphous solid dispersion involves dispersing the drug in a polymer matrix. Lipid-based formulations utilize lipids or surfactants. Cyclodextrin complexation involves forming inclusion complexes between the drug and cyclodextrin molecules to improve solubility. Salt

ISSN 2515-8260 Volume 05, Issue 01, 2018

formation involves converting the drug into a salt form to enhance its solubility and dissolution rate

Literature review

Bioavailability refers to the absorption rate and extent, or the amount of unchanged drug absorbed from its dosage form. According to Khan and Singh (2016), the The utilization of diverse methodologies to enhance the bioavailability of substances is a pivotal factor in achieving optimal concentrations of drugs within the systemic circulation, thus facilitating a desired pharmacological response. The inadequate bioavailability of drugs is frequently linked to various factors, encompassing insufficient solubility in aqueous environments, sluggish dissolution rates, instability of dissolved compounds under physiological pH conditions, limited permeation across biological membranes, and extensive metabolism during the initial pass through the body. Drugs characterized by low solubility in water necessitate high dosages to achieve therapeutically effective plasma concentrations when administered orally. The formulation development process for novel drugs often encounters substantial hurdles due to their suboptimal water solubility. To ensure the effective performance of a drug, it is imperative that it assumes an aqueous solution form at the site of absorption.

The pharmaceutical industry has seen the increased employment of finely divided substances, primarily drugs, to advance dissolution, solubility, and bioavailability. Loh et al. (2015) noted that the solubility of water-insoluble drugs has been improved by milling processes. Different techniques and apparatus can be used to reduce the size of drug particles, and many of these can be scaled up to produce consistent and perpetual manufacturing. The use of Process Analytical Technology (PAT) tools when milling has promoted better perception of the process and enables the tracking and regulation of the particle size reduction process. This helps to generate fine particles with controllable and foreseeable physicochemical characteristics. Nevertheless, this concentrates on only a few facets of milling, and there are many other elements worthy of consideration.

The pharmaceutical industry has seen the increased employment of finely divided substances, primarily drugs, to advance dissolution, solubility, and bioavailability. Loh et al. (2015) noted that the solubility of water-insoluble drugs has been improved by milling processes. Different

ISSN 2515-8260 Volume 05, Issue 01, 2018

techniques and apparatus can be used to reduce the size of drug particles, and many of these can be scaled up to produce consistent and perpetual manufacturing. The use of Process Analytical Technology (PAT) tools when milling has promoted better perception of the process and enables the tracking and regulation of the particle size reduction process. This helps to generate fine particles with controllable and foreseeable physicochemical characteristics. Nevertheless, this concentrates on only a few facets of milling, and there are many other elements worthy of consideration.

The solubility of poorly water-soluble drugs is a major issue when it comes to their bioavailability and therapeutic effectiveness. To overcome this difficulty, a number of different methods have been developed, such as forming binary systems with cyclodextrins (CDs). These complexes can modify the physical and chemical traits of the drugs, such as dissolution properties, size, crystal shape, and thermal characteristics, leading to amorphous forms with a higher degree of solubility in water. This approach promises great potential for improving the solubility of water-insoluble drugs.

The most popular means of delivering drugs is orally, according to Krishnaiah (2010). Using this approach, particle size and distribution can be effectively managed, and the dissolution, bioavailability, and stability of the final product can be adjusted without the use of solvents. Additionally, there have been advances made in milling techniques to provide more precise control of the crystallization process of drugs. This allows for polymorphs, hydrates, solvates, nanoparticles, and pharmaceutical co-crystals to be formed, all of which have improved oral bioavailability. Furthermore, the implementation of supercritical fluid technologies is ongoing to enable the large-scale manufacture of micronized particles to increase bioavailability for drugs that have limited solubility.

A promising emerging technique, referred to as melt sonocrystallization, harnesses the power of ultrasonic energy to fabricate porous particles that dissolve rapidly, particularly targeting drugs classified under BCS Class II. Extensive research on solid dispersion techniques has paved the way for the development of novel technologies aimed at enhancing the dissolution rate of poorly soluble drugs. These advancements hold promise for improving drug solubility and bioavailability, opening new avenues for drug delivery and formulation strategies.

ISSN 2515-8260 Volume 05, Issue 01, 2018

Oral drug administration hinges on the capacity of drugs to endure the arduous journey through the gastrointestinal (GI) tract. While a certain level of absorption takes place within the oral cavity and stomach, it is primarily the small intestine that assumes the mantle of being the principal site for absorption. Alas, the attainment of optimal bioavailability presents a formidable hurdle in the pursuit of efficacious oral therapies. The bioavailability of a drug administered orally is heavily swayed by its intrinsic properties and the physiological milieu it traverses.

The use of a drug demands that it be able to withstand the powerful effects of gastrointestinal pHs and enzymes. This complex process includes the production of micelles, which are brought about by a decrease in energy. This means that they remove hydrophobic portions from the water and are formed by a reorganized hydrogen bond in liquid. To encapsulate those drugs which are not well-soluble in water, several strategies can be employed, such as dialysis, emulsion solvent evaporation, and solid dispersion.

Xu, Ling, & Zhang, (2013) oral administration is the preferred route for drug delivery, the ability of particulate materials (PMs) to facilitate the delivery of medications that have trouble dissolving in water, particularly those that need to be dosed various times. PMs help delivery by protecting the drug from the hostile environment of the gastrointestinal tract and regulating its release and absorption. As PMs are stable both in the short-term and long-term, the medications are secure throughout transit. Furthermore, pH-sensitive PMs can streamline drug release in certain areas, while mucoadhesive PMs can extend the amount of time the drug spends in the gut. Additionally, PMs have the capacity to inhibit P-gp, allowing the drug concentration to be increased.

The emergence of combinatorial chemistry has wielded a profound influence on the field of pharmaceutical exploration, fundamentally transforming the capacity to synthesize a considerable multitude of compounds on an annual basis. Freeze fracture often leads to changes in the shape of liposomes because the process of preparing specimens involves physical stress. Environmental scanning electron microscopy (ESEM) is a potential solution to this problem, as it allows researchers to view aqueous systems without any previous alteration of the sample. In addition, ESEM makes it possible to alter the conditions of the sample with regards to gas composition, temperature, and pressure. This method of microscopy has already been beneficial in the study of damp specimens.

ISSN 2515-8260 Volume 05, Issue 01, 2018

The incorporation of the poorly water-soluble drug ibuprofen into PC:Chol liposomes was found to be influenced by various factors within the multilamellar vesicle (MLV) formulation. These factors include the cholesterol content in the lipid bilayer, the length of the lipid alkyl chains, and the presence of charged lipid headgroups.

According to Mohammed, Weston, Coombes, Fitzgerald, and Perrie (2004), The optimal encapsulation of water-soluble drugs necessitated the development of a liposome formulation. To ideal drug loading, a multidrug-loaded vesicle (MLV) composed of 20% cholesterol (based on the overall lipid content) and 9% stearylamine proved effective. Alternatively, substituting phosphatidylcholine with long alkyl chain lipids like dilignoceroyl phosphatidylcholine (C24PC) also yielded favorable results. The inclusion of extended alkyl chain length PC led to improved retention of ibuprofen within the liposomes, whereas the incorporation of charged lipids had a diminishing effect. A minimal rise of approximately 10% in the medium vesicle size diameter was observed due to the inclusion of ibuprofen in PC:Chol liposomes, yet this yielded no major consequence on the zeta potential of the different liposome formulations that were evaluated. ESEM analysis demonstrated that liposomes loaded with ibuprofen exhibited greater structural stability during dehydration compared to drug-free liposomes. This finding suggests a direct influence of drug/lipid binding on the stability of the liposome bilayer. These studies also confirm the usefulness of ESEM in real-time monitoring of liposome morphology changes during dehydration, presenting an alternative assay method. Pharmaceutical particle technology plays a crucial role in enhancing the bioavailability of drug compounds with poor aqueous solubility. These compounds often exhibit low dissolution rates in the gastrointestinal fluids when taken orally, limiting their effectiveness. Particle technology encompasses various approaches, ranging from traditional size reduction methods to innovative techniques that modify the solubility properties of drugs. By transforming them into solid, powdered forms that readily dissolve in water, these technologies enable easy formulation into different dosage forms. Khadka et al., (2014) address the issue of poor aqueous solubility, pharmaceutical particle technologies offer diverse solutions. Traditional methods primarily revolve around mechanical micronization techniques, employing straightforward and convenient processes for reducing the size of drug particles. This, in turn, augments the surface area of the particles, thereby amplifying their solubility and dissolution properties. Nonetheless, conventional particle technologies exhibit certain constraints, such as limited efficiency, which may potentially

ISSN 2515-8260 Volume 05, Issue 01, 2018

trigger thermal and chemical degradation of drugs, alongside the issue of uneven particle sizes. On the contrary, a newer and more imaginative arsenal of particle techniques has emerged to circumvent the limitations inherent in conventional methodologies and offer more efficacious avenues for formulating poorly soluble drugs. These groundbreaking innovations are rooted in the principles of dimensional reduction, aiming to optimize the dissolvability of such compounds.

Pouton, (2006) entail the utilization of polymers, cyclodextrins, and liposomes, which have exhibited promising outcomes in augmenting both the solvency and durability of medicinal compositions. Each particle technology offers distinctive advantages and applications in advancing the water solvency of inadequately aqueous soluble medications. The choice of an appropriate approach relies on the specific attributes of the medication being formulated and the intended form of dosage.While current pharmaceutical particle technologies provide valuable solutions, the field continues to explore additional methods for formulating drugs with poor aqueous solubility. Ongoing research aims to uncover new possibilities and further expand the applications of pharmaceutical particle technology.

Conclusion

The conceptualization and design of pharmaceutical compounds hold paramount significance in elevating the dissolvability, durability, and accessibility of drugs characterized by restricted aqueous solubility. This analytical standpoint casts illumination upon the intricacies entwined with such pharmacological substances and the approaches harnessed to surmount these formidable hurdles. Enhancing the solubility of drugs assumes utmost eminence in facilitating optimal absorption and therapeutic efficacy. Various methodologies, encompassing solid dispersion, nano-sizing, cyclodextrin complexation, and lipid-based formulations, have been proficiently employed to ameliorate the solubility of drugs. These modalities facilitate the metamorphosis of inadequately soluble drugs into more amenable forms, thus engendering escalated dissolution rates and amplified bioavailability. Moreover, stability is a vital aspect to ensure the shelf-life and efficacy of pharmaceutical products. Formulation design can address stability issues by incorporating excipients that provide protection against degradation, such as antioxidants and stabilizers. Additionally, the selection of appropriate manufacturing processes and packaging materials is crucial to maintain drug stability over time. Bioavailability, which encompasses both solubility and stability, determines the extent and rate at which a drug reaches systemic circulation.

ISSN 2515-8260 Volume 05, Issue 01, 2018

Through the implementation of formulation strategies, bioavailability can be significantly improved, resulting in more predictable and efficient drug delivery.

Advancements in analytical techniques have played a pivotal role in understanding the physicochemical properties of poorly soluble drugs and evaluating the effectiveness of formulation approaches. Techniques such as spectroscopy, chromatography, and particle size analysis have provided valuable insights into drug characteristics and formulation performance. formulation design for enhancing solubility, stability, and bioavailability of poorly water-soluble drugs is a multifaceted and complex endeavour. The amalgamation of analytical perspectives and ground-breaking formulation strategies can pave the path towards the fabrication of efficacious pharmaceutical products endowed with enhanced therapeutic outcomes. Sustained research endeavours and collaborative synergy among scientists, pharmacists, and regulatory authorities shall indubitably contribute to the progression of this realm, ultimately bestowing benefits upon patients across the globe.

References

1. Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., & Onoue, S. (2011). Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. *International journal of pharmaceutics*, *420*(1), 1-10.
2. Fahr, A., & Liu, X. (2007). Drug delivery strategies for poorly water-soluble drugs. *Expert opinion on drug delivery*, *4*(4), 403-416.
3. Khan, A. D., & Singh, L. (2016). Various techniques of bioavailability enhancement: a review. *Journal of Drug Delivery and Therapeutics*, *6*(3), 34-41.
4. Loh, Z. H., Samanta, A. K., & Heng, P. W. S. (2015). Overview of milling techniques for improving the solubility of poorly water-soluble drugs. *Asian journal of pharmaceutical sciences*, *10*(4), 255-274.
5. JS, P., Kadam, D. V., Marapur, S. C., & Kamalapur, M. V. (2010). Inclusion complex system; a novel technique to improve the solubility and bioavailability of poorly soluble drugs: a review. *Int. J. Pharm. Sci. Rev. Res*, *2*, 29-34.
6. Krishnaiah, Y. S. (2010). Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. *J Bioequiv Availab*, *2*(2), 28-36.

ISSN 2515-8260 Volume 05, Issue 01, 2018

7. Xu, W., Ling, P., & Zhang, T. (2013). Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. *Journal of drug delivery*, *2013*.
8. Mohammed, A. R., Weston, N., Coombes, A. G. A., Fitzgerald, M., & Perrie, Y. (2004). Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. *International journal of pharmaceutics*, *285*(1-2), 23-34.
9. Khadka, P., Ro, J., Kim, H., Kim, I., Kim, J. T., Kim, H., ... & Lee, J. (2014). Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. *Asian journal of pharmaceutical sciences*, *9*(6), 304-316.
10. Pouton, C. W. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. *European journal of pharmaceutical sciences*, *29*(3-4), 278-287.
11. Pouton, C. W. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. *European journal of pharmaceutical sciences*, *29*(3-4), 278-287.
12. Merisko-Liversidge, E., & Liversidge, G. G. (2011). Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. *Advanced drug delivery reviews*, *63*(6), 427-440.